Indogulf Cropsciences Earnings Call Transcript: Key Takeaways
Q2 revenue +3% to ₹255.8 Cr; EBITDA +27%, margin 16% (13%) on mix and cost cuts. H1 revenue -3%, negative operating cash flow, inventory elevated.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Q2 revenue +3% to ₹255.8 Cr; EBITDA +27%, margin 16% (13%) on mix and cost cuts. H1 revenue -3%, negative operating cash flow, inventory elevated.
Indogulf Cropsciences reported Q2 FY27 EBITDA of ₹41 Cr (up 27%) and PAT of ₹26 Cr (up 24%). Margin expanded 300 bps to 16% on favourable product mix.
Indogulf Cropsciences filed its Monitoring Agency Report for the quarter ended September 30, 2026, covering IPO proceeds of Rs 200 crore. The report states no deviation from the objects of the issue.
Q2 FY27 revenue up 3% YoY to INR 2,558 Mn; EBITDA up 27% to 406 Mn (15.9% margin); PAT up 24% to 257 Mn. H1 revenue down 3%.
Indogulf Cropsciences Ltd reported revenue from operations of ₹255.8 Cr (+3.0% YoY) and net profit of ₹25.7 Cr (+24.2% YoY) for Q2 FY27.
Indogulf Cropsciences will hold a board meeting on 2 November 2026 to consider unaudited standalone and consolidated results for the quarter ended September 2026. The trading window closes from 1 October 2026.
The company submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, as per Regulation 31 of SEBI Listing Regulations.
Indogulf Cropsciences re-appointed Pushap Kumar as Non-Executive Director and appointed M/s NJ & Associates as Secretarial Auditor for five years.
Indogulf Cropsciences Limited announced the re-appointment of Mr. Pushap Kumar as Non-Executive Non-Independent Director and the appointment of M/s. NJ & Associates as Secretarial Auditor.
Indogulf Cropsciences Ltd. conducted its 34th Annual General Meeting. Shareholders approved financial statements, director re-appointment, auditor matters, and variation in IPO proceeds utilization.